Monthly Risperdal Consta: J&J’s Paliperidone Fallback?
This article was originally published in The Pink Sheet Daily
Executive Summary
Partner Alkermes discloses latest schizophrenia-drug strategy.
You may also be interested in...
Paliperidone Palmitate Launch Unlikely Until 2010, J&J Says
New dosing option for the atypical antipsychotic will be included in the NDA resubmission.
Paliperidone Palmitate Launch Unlikely Until 2010, J&J Says
New dosing option for the atypical antipsychotic will be included in the NDA resubmission.
J&J's Paliperidone Gets "Complete Response" Letter From FDA
No more studies are required, but FDA outlined questions that need to be addressed, according to J&J